Analysts Set Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Target Price at $18.25

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) has been given a consensus rating of “Moderate Buy” by the nine research firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $18.25.

ADPT has been the topic of a number of research analyst reports. Guggenheim lifted their price target on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Wednesday, January 21st. BTIG Research upped their price target on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a “buy” rating in a research report on Friday, February 6th. Piper Sandler set a $21.00 price target on shares of Adaptive Biotechnologies in a research note on Friday, February 6th. Finally, Morgan Stanley started coverage on Adaptive Biotechnologies in a research note on Monday, December 1st. They set an “equal weight” rating and a $21.00 price objective for the company.

Adaptive Biotechnologies Stock Down 0.2%

Shares of Adaptive Biotechnologies stock opened at $16.08 on Friday. The firm has a market cap of $2.48 billion, a PE ratio of -40.20 and a beta of 2.19. Adaptive Biotechnologies has a twelve month low of $6.26 and a twelve month high of $20.76. The business has a 50-day moving average price of $16.85 and a 200 day moving average price of $15.79.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.10. The company had revenue of $71.68 million for the quarter, compared to the consensus estimate of $59.38 million. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.Adaptive Biotechnologies’s revenue for the quarter was up 51.0% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.23) earnings per share. On average, sell-side analysts expect that Adaptive Biotechnologies will post -0.92 EPS for the current year.

Insider Transactions at Adaptive Biotechnologies

In other news, insider Harlan S. Robins sold 34,668 shares of the company’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $18.60, for a total transaction of $644,824.80. Following the completion of the sale, the insider owned 1,187,644 shares of the company’s stock, valued at $22,090,178.40. This represents a 2.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Sharon Benzeno sold 12,604 shares of the firm’s stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $16.85, for a total transaction of $212,377.40. Following the completion of the transaction, the insider directly owned 296,791 shares in the company, valued at approximately $5,000,928.35. This represents a 4.07% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 1,080,788 shares of company stock worth $17,712,147 in the last quarter. 6.40% of the stock is owned by insiders.

Institutional Trading of Adaptive Biotechnologies

A number of hedge funds have recently bought and sold shares of the business. Ameriprise Financial Inc. lifted its stake in Adaptive Biotechnologies by 84.3% in the 3rd quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock worth $89,337,000 after purchasing an additional 2,731,648 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in Adaptive Biotechnologies by 303.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock worth $71,252,000 after buying an additional 3,299,635 shares in the last quarter. Westfield Capital Management Co. LP acquired a new position in Adaptive Biotechnologies during the fourth quarter worth $65,942,000. Geode Capital Management LLC grew its holdings in Adaptive Biotechnologies by 3.3% in the 4th quarter. Geode Capital Management LLC now owns 3,511,855 shares of the company’s stock valued at $57,041,000 after buying an additional 110,825 shares in the last quarter. Finally, State Street Corp grew its holdings in Adaptive Biotechnologies by 3.3% in the 4th quarter. State Street Corp now owns 3,181,644 shares of the company’s stock valued at $51,670,000 after buying an additional 102,362 shares in the last quarter. Institutional investors and hedge funds own 99.17% of the company’s stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.